The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
about
Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormoneImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisCorticosteroids for the long-term treatment in multiple sclerosisGlucocorticoids and endothelial cell barrier functionNeuroendocrine immunoregulation in multiple sclerosisDiagnosis and Management of Multiple Sclerosis in ChildrenTherapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Methylprednisolone Administration Following Spinal Cord Injury Reduces Aquaporin 4 Expression and Exacerbates Edema.The effect of pulse methylprednisolone plus theophylline treatment on clinical, pulmonary and inflammatory markers in relapses of multiple sclerosisDrug therapy for multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding.Long-term prevalence of NIRF-labeled magnetic nanoparticles for the diagnostic and intraoperative imaging of inflammation.Brain-immune communication psychoneuroimmunology of multiple sclerosis.Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects.One-time intrathecal triamcinolone acetonide application alters the redox potential in cerebrospinal fluid of progressive multiple sclerosis patients: a pilot study.Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisoloneTransplantation of Human Embryonic Stem Cells in Patients with Multiple Sclerosis and Lyme Disease.Chemokines and chemokine receptors in multiple sclerosis.Rehabilitation interventions in multiple sclerosis: an overview.Corticosteroids in the management of acute multiple sclerosis exacerbations.Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.A combination of simvastatin and methylprednisolone improves the quality of vitrified-warmed ovarian tissue after auto-transplantation.Influence of treatment in multiple sclerosis disability: an open, retrospective, non-randomized long-term analysis.Cerebrovascular hemodynamic changes in multiple sclerosis patients during head-up tilt table test: effect of high-dose intravenous steroid treatment.Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis.Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.Cerebral Oedema, Blood-Brain Barrier Breakdown and the Decrease in Na(+),K(+)-ATPase Activity in the Cerebral Cortex and Hippocampus are Prevented by Dexamethasone in an Animal Model of Maple Syrup Urine Disease.Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells.Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex.Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice.Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years
P2860
Q21558407-6A4BE971-BA3D-4AED-8C33-3A38CFF15411Q24202108-DAC3C1DA-1469-42DD-9C34-69AB28582D4EQ24235249-3A1688EC-7A68-4729-90A3-3C0BE2A2B2CEQ24242150-4546591E-D555-4650-9546-3FB0D43D5D2BQ26853743-2F118FF2-A080-4C73-BBA0-B2511ABFC5C2Q26864449-B9EB44E4-C820-460D-B554-CBFF4381FA49Q28069571-F1C340E0-8762-44EE-80F6-25C26B9A47DAQ30354658-459F0AA0-60CA-4C0D-BDD7-9DD8DE9DB659Q33721285-AA14B971-FEBC-44E8-8F9F-61B248577A8BQ33974404-396E5B1F-6019-4881-89B9-2530AC5E2E47Q33990246-B246304D-DD66-4EC2-83FA-2ABC21A5F807Q34468304-6C27AD6D-8753-4E0B-909E-144D04DD8751Q35742927-3F55EFA0-3B8C-4323-9BBD-98BB9C362CA7Q36688987-D098BA51-DF2A-438E-848E-B2D39CE059D5Q36761866-B2A51D14-61BA-4C2B-8AB6-704BD2D61792Q36946327-7BA11A6C-747A-4446-A798-61A5DDDBA063Q36963171-A32CC489-D09B-43B1-8C61-51A561064336Q37027679-2F5E028C-A723-4CBB-95AA-C5063C930156Q37309086-0E630DDC-83E5-47E5-BE43-7296267C66A6Q37503496-8CA4F6CF-9DA7-4D4F-B5A3-B9EC34C1BB3BQ37594837-A4B90BF3-BA27-406D-B00A-96D304680135Q38024650-65592D5E-890A-46C6-A2AF-9E395892EA56Q39229363-20872EF4-0896-4617-AC84-6F0BEFCCBE92Q39349492-D78B8774-B6FF-49F7-8D1A-F9C592407168Q41002593-29350BD7-5911-42E1-A3A7-F9698ACFF06FQ41600323-845C1CC0-F791-4D63-8380-D3E6DF83206DQ42929708-B9D4B411-FF3C-43EA-9D5A-58BBAB2A2036Q44554628-991E5A18-39F5-4DB4-9D84-B164BBFD04F6Q45076147-737EE00C-7396-4F7C-A089-628444B78239Q46524435-B9D9CEB3-15C1-4DAA-8F84-38A5234FED5BQ46528181-5DED922B-2A83-43AE-A082-C1D0D17880B4Q46609780-359C35CD-989C-4E9F-84CC-C227D3823765Q47736322-0C0F5786-8488-460C-8E86-DB1B4B80007CQ48099910-29631E4E-AC7D-41DD-BA0C-CEF42581AA43Q51218322-C4F81A4D-366D-4364-8756-515E740A1FC5Q52372446-24DD5D3B-1080-40C8-B462-2F28844807AAQ53470127-33E6DEA3-EE01-4650-8802-4D72DF979590Q54363020-ABF306D4-6348-4FB4-9B17-2429D1604324Q56698310-E03F4911-AEB2-460E-BB53-84C62DA54F39
P2860
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@ast
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@en
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@nl
type
label
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@ast
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@en
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@nl
prefLabel
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@ast
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@en
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@nl
P2860
P1476
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.
@en
P2093
M Stefanelli
P2860
P304
P356
10.1191/1352458505MS1190OA
P577
2005-08-01T00:00:00Z